Evidence map›Paper›PMID 42105121›Full record

ArticleJournal of bone and mineral metabolism2026

A comparative analysis of osteoporosis, nephrolithiasis, and metabolic/cardiovascular comorbidities in normocalcemic and mild primary hyperparathyroidism.

Mazhar Müslüm Tuna, İsmail Engin, Özden Uzun, Sevde Nur Fırat, Özge Kimyon, Elif Güneş, Kadircan Karatoprak, Ümit Nur Özbay, Ziynet Alphan Üç, Ali Yeşiltepe and 9 more

Abstract readComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of bone and mineral metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Mazhar Müslüm TunaDepartment of Endocrinology and Metabolism, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey. mazharmuslum.tuna@sbu.edu.tr.ORCID http://orcid.org/0000-0001-5975-7786
İsmail EnginDepartment of Endocrinology and Metabolism, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey.
Özden UzunDepartment of Endocrinology and Metabolism, Faculty of Medicine, Tekirdag Namık Kemal University, Tekirdag, Turkey.
Sevde Nur FıratDepartment of Endocrinology and Metabolism, University of Health Sciences, Turkey, Ankara Training and Research Hospital, Ankara, Turkey.
Özge KimyonDepartment of Endocrinology and Metabolism, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
Elif GüneşDepartment of Endocrinology and Metabolism, Bursa Training and Research Hospital, Bursa, Turkey.
Kadircan KaratoprakDepartment of Endocrinology and Metabolism, Faculty of Medicine, Uludag University, Bursa, Turkey.
Ümit Nur ÖzbayDepartment of Endocrinology and Metabolism, Faculty of Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.
Ziynet Alphan ÜçDepartment of Endocrinology and Metabolism, Usak Training and Research Hospital, Usak, Turkey.
Ali YeşiltepeDepartment of Endocrinology, Kutahya Health Science University, Kutahya, Turkey.
Şevkican GüneşDivision of Endocrinology and Metabolism, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Sayid Shafi ZuhurDepartment of Endocrinology and Metabolism, Faculty of Medicine, Tekirdag Namık Kemal University, Tekirdag, Turkey.
Hüseyin YağcıDepartment of Endocrinology and Metabolism, University of Health Sciences, Turkey, Ankara Training and Research Hospital, Ankara, Turkey.
Evin BozkurDepartment of Endocrinology and Metabolism, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
Özen Öz GülDepartment of Endocrinology and Metabolism, Faculty of Medicine, Uludag University, Bursa, Turkey.
Ayten OğuzDepartment of Endocrinology and Metabolism, Faculty of Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.
Cevdet DuranDepartment of Endocrinology and Metabolism, Usak Training and Research Hospital, Usak, Turkey.
Barış Güven CansuDepartment of Endocrinology, Kutahya Health Science University, Kutahya, Turkey.
Nurdan GülDivision of Endocrinology and Metabolism, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNormocalcemic primary hyperparathyroidism (NPHPT) is thought to be an early form of hypercalcemic primary hyperparathyroidism (PHPT). However, some studies have shown that the adverse effects on bone and kidney health are similar in both conditions. MATERIALS AND

methodsThis is a nationwide, multicentre, retrospective study. Data from centres, including 404 patients with NPHPT and 723 patients with mild PHPT from different regions of Turkey, were included in this study. All laboratory parameters, dual-energy X-ray absorptiometry, and renal ultrasounds were performed locally at each centre. The prevalence of adverse bone and kidney outcomes and metabolic and cardiovascular comorbidities were the main outcome measures.

resultsPatients with NPHPT had lower calcium and PTH levels. Skeletal outcomes revealed 29% osteoporosis and 42% osteopenia, while the prevalence of nephrolithiasis was 12.4%, which is similar to that observed in patients with mild PHPT. Hypertension was more prevalent in patients with mild PHPT than in those with NPHPT (44.4% vs. 34.9%, p = 0.002), as was diabetes mellitus (27.9% vs. 13.2%, p < 0.001). The prevalence of cardiovascular disease was similar (11.5% vs. 9.5%, p = 0.306).

conclusionPatients with NPHPT experience significant skeletal complications and nephrolithiasis but have lower rates of hypertension and diabetes.

Indexed as

CalciumCardiovascular DiseasesHyperparathyroidism, PrimaryNephrolithiasisOsteoporosisAgedComorbidityFemaleHumansMaleMiddle AgedRetrospective StudiesTurkeyCalciumHypercalcemiaNephrolithiasisNormocalcemic primary hyperparathyroidismOsteoporosisPrimary hyperparathyroidism

Identifiers

PMID42105121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.